COVID-19 PATIENT SAMPLE ACCESS

BACKGROUND

The University of Utah COVID Biorepository is a resource to access human biological samples from individuals who have been infected with COVID-19. The details of the contributing studies and samples are listed on pg. 2.

INSTITUTATIONAL REGULATORY APPROVALS

To access the samples, you **must** obtain approval from the Institutional Biosafety Committee (IBC).

You will also need approval from the Institutional Review Board (IRB).

- - You will need to submit a **human subjects application** through ERICA if you are requesting access to identifiable data.
- - You will need to a **non-human subjects application** through ERICA if you are requesting access to limited or de-identified data.

Learn more about data identifiability here.

If you are requesting access to identifiable data, you will need to reference the study/studies under which the samples were collected. You will also need to provide justification for how your research fits within the allowable future research for each study. These details are provided in the table on pg. 2.

For questions, contact Sara Salmon (sara.salmon@hsc.utah.edu).

COVID-19 PATIENT SAMPLE ACCESS

DETAILS OF COLLECTING STUDIES

ID	Name	Principal Investigator	Patient characteristics	Types of Samples	Types of Future research allowed on the samples
IRB_00093575	INFO: Inflammatory and Fibrotic Disease and Response Collection protocol	Scholand	Hospitalized	-peripheral blood will be collected, separated into serum / plasma / peripheral blood mononuclear cells (PBMCs) / platelets	Future research for inflammatory and fibrotic disease or response will be allowed on these samples
IRB_00102638	PRAISe: Platelet Immune Responses in Aging and Influenza and Sepsis	Middleton	Critically ill, ICU, inpatient	-peripheral blood will be collected, separated into serum / plasma / peripheral blood mononuclear cells (PBMCs) / platelets -Tracheal aspirate fluid	Future research may include inflammation, infection and platelets
IRB_00131664	Detection of Immunity to COVID-19 in Peripheral Blood of Convalescing Individuals	Spivak	Convalescent, non-hospitalized	-peripheral blood will be collected, separated into serum / plasma / peripheral blood mononuclear cells (PBMCs)	Immunology assays (for example, detection of the presence of neutralization antibodies or immune cell activation) genetic and epigenetic assays
IRB_00131893	Hydroxychloroquine for Outpatients with Confirmed COVID-19 (HCQ Trial)	Spivak	Acute COVID illness, non-hospitalized	**Deidentified*** plasma and peripheral blood mononuclear cells (PBMC). *Note: all samples will be de-identified before being sent to the bio-repository.	The samples will be primarily used to better understand COVID-19, but may also be used to understand other diseases or develop new scientific methods. Examples include, but are not limited to, the immune response to SARS-CoV-2, drug screening, investigation of viral biology, cardiac biomarkers, and development of diagnostic assays.